Zhang Lufei, He Tianyu, Yan Yingcai, Zhang Yuan, Zhou Xiaohu, Huang Pengfei, Kong Yang, Xie Minjie, Zhang Linshi, Sun Qiang, Zhou Dongkai, Xie Haiyang, Zhou Lin, Zheng Shusen, Wang Weilin
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; Key Laboratory of Combined Multiorgan Transplantation, Ministry of Public Health, Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Biomed Res Int. 2016;2016:3608914. doi: 10.1155/2016/3608914. Epub 2016 Nov 8.
Long noncoding RNAs (lncRNAs) play crucial roles in cancer occurrence and progression. However, the relationship between the expression levels of lncRNAs and the hepatocellular carcinoma (HCC) process is unclear. The goal of this study was to determine the expression level of ZNF674-AS1, a newly found lncRNA, in HCC and its clinical association. The expression of ZNF674-AS1 in 137 pairs of tumorous and adjacent normal tissues from patients with HCC was detected by quantitative real-time reverse transcription polymerase chain reaction. Additionally, the potential associations between its level in HCC tissue and clinicopathological features were analyzed. The expression of ZNF674-AS1 in the HCC cell lines HepG2, HCCLM3, SK-Hep1, HuH7, Hep3B, and MHCC97H was significantly downregulated compared with that in the normal liver cell line QSG-7701. The expression of ZNF674-AS1 was downregulated in 72% (99/137) of HCC tissues compared with that in paired adjacent normal tissues ( < 0.01). The results showed that the ZNF674-AS1 expression level was significantly correlated with metastasis ( = 0.041), clinical stage ( = 0.039), and histopathologic grading ( = 0.045). In addition, the Kaplan-Meier survival curves revealed that low ZNF674-AS1 expression was associated with poor prognosis in patients with HCC. Our data suggest that ZNF674-AS1 may play some role during cancer occurrence and progression and may be a new biomarker for HCC.
长链非编码RNA（lncRNAs）在癌症的发生和发展过程中发挥着关键作用。然而，lncRNAs的表达水平与肝细胞癌（HCC）进程之间的关系尚不清楚。本研究的目的是确定一种新发现的lncRNA——ZNF674-AS1在HCC中的表达水平及其临床相关性。通过定量实时逆转录聚合酶链反应检测了137对HCC患者的肿瘤组织和癌旁正常组织中ZNF674-AS1的表达。此外，分析了其在HCC组织中的水平与临床病理特征之间的潜在关联。与正常肝细胞系QSG-7701相比，ZNF674-AS1在HCC细胞系HepG2、HCCLM3、SK-Hep1、HuH7、Hep3B和MHCC97H中的表达显著下调。与配对的癌旁正常组织相比，72%（99/137）的HCC组织中ZNF674-AS1的表达下调（<0.01）。结果表明，ZNF674-AS1的表达水平与转移（=0.041）、临床分期（=0.039）和组织病理学分级（=0.045）显著相关。此外，Kaplan-Meier生存曲线显示，ZNF674-AS1低表达与HCC患者的预后不良相关。我们的数据表明，ZNF674-AS1可能在癌症发生和发展过程中发挥一定作用，可能是HCC的一种新的生物标志物。
